Bcl-2 Heterodimer Antibody for Cancer Drug Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face variability in response due to different heterodimer formations between Bcl-2 proteins in cancer cells, making it challenging to determine patient responsiveness to apoptosis-inducing drugs.
Innovation Solution
Development of an isolated antibody specifically binding to Bcl-2 heterodimers, allowing for their detection in tissue samples and prediction of patient sensitivity or resistance to drugs that interfere with heterodimer formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If different cancer cells have different heterodimer formations between Bcl-2 proteins, then the response to apoptosis-inducing drugs varies, but it becomes difficult to determine patient responsiveness
Solution Approach 1:
The patent uses a specifically designed antibody as an intermediary tool to detect Bcl-2 heterodimers. This antibody binds selectively to the heterodimer structure formed by pro-apoptotic and anti-apoptotic Bcl-2 proteins, enabling researchers to determine which heterodimers are present in patient samples. By using this antibody mediator, the complex heterodimer detection problem is simplified into a straightforward binding assay that can predict drug responsiveness reliably.
2Measurement precision
If an antibody is designed to specifically bind to Bcl-2 heterodimers, then accurate detection of heterodimers is achieved, but the antibody development process becomes complex
Solution Approach 1:
The patent employs preliminary action by first expressing and purifying the Bcl-2 heterodimer structure in a controlled laboratory setting before using it to generate the specific antibody. The heterodimer is formed by co-expressing pro-apoptotic and anti-apoptotic Bcl-2 proteins in a cell system, purifying the resulting heterodimer complex, and then using this purified heterodimer as the immunogen to raise the specific antibody. This preliminary preparation of the exact target structure ensures high measurement precision in subsequent detections.
3Adaptability or versatility
If the presence of different heterodimers determines drug responsiveness, then personalized treatment assessment is possible, but the detection method must be highly specific
Solution Approach 1:
The patent applies local quality by designing the antibody to recognize a specific local structural feature of the Bcl-2 heterodimer interface. Rather than attempting to recognize the entire complex protein structure, the antibody targets a particular epitope formed at the interaction interface between the pro-apoptotic and anti-apoptotic Bcl-2 proteins. This localized recognition ensures high specificity for heterodimers while allowing the method to be adapted to detect different heterodimer combinations for personalized treatment assessment.
Data Source
AI summary
Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.